MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm, Inc. (“Pediapharm”) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements to acquire two speciality pharmaceutical companies and also intends to complete a private placement offering for up to CDN$60 million.

Pediapharm logo

PEDIAPHARM is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community.

Medexus logo

MEDEXUS is a Canadian specialty pharmaceutical company focused on the licensing, registration, marketing, sales and distribution of innovative pharmaceutical products in Canada.

Medexus Pharm logo

MEDEXUS PHARMA is a specialty pharmaceutical company focusing on the development and commercialization of treatments for autoimmune diseases and oncology in the United States.


What's New

May 14, 2019
Medexus Pharmaceuticals Announces Normal Course Issuer Bid
Read More >

May 7, 2019
Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg
Read More >

April 23, 2019
Medexus CEO to Present at Two Upcoming Investor Conferences
Read More >


Medexus Pharmaceuticals Inc., D, TSXV